Citius Oncology, Inc. (CTOR NASDAQ) stock market data APIs
$1.376
-0.13(-9.4%)
as of December 19, 2025
Try our APIs with
free plan!
Citius Oncology, Inc. Financial Data Overview
Price chart is built with
Anychart
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Prev. Close
1.376
Open
1.2414
High
1.4373
Low
1.1642
52 wk Range
0.551-6.19
Market Cap
118 M
Shares Outstanding
84 798 K
EPS
-0.08
Beta
2.991
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Citius Oncology, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Citius Oncology, Inc. data using free add-ons & libraries
Get Citius Oncology, Inc. Fundamental Data
Citius Oncology, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Citius Oncology, Inc. News
New
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
AUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. hea...
Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years
(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the U.S. commercial launch of LYMPHIR, a new immunotherapy for adults with relapsed or...
Citius Oncology rises after U.S. launch of Lymphir as a cancer treatment
[Cancer cell view] * Citius Oncology (CTOR [https://seekingalpha.com/symbol/CTOR]) shares jumped after the commercial launch of its immunotherapy Lymphir, a late-line option for cutaneous T-cell...
How Investors Are Reacting To McKesson (MCK) Securing LYMPHIR’s Distribution Ahead of U.S. Launch
In October 2025, Citius Oncology announced a distribution services agreement with McKesson, making McKesson an authorized distributor of record for LYMPHIR, a newly FDA-approved immunotherapy for cert...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
